REPORT
Nobel Med 2008; 4(1): 28-30

A CASE REPORT OF BONE MARROW SUPPRESSION CAUSED BY PIPERACILLIN TAZOBACTAM

Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay
ABSTRACT
Piperacillin/tazobactam (PT) is a commonly prescribed antibiotic and is generally considered safe. During treatment with piperacillin/tazobactam bone marrow suppression can rarely be seen as a serious adverse effect. We report here a case of PT induced bone marrow suppression. A 58 year old man was being treated with PT for empyema. After 20 days of treatment, he developed neutropenia and thrombocytopenia.

The findings reversed promptly after cessation of PT. The time of course of events suggested that PT was the cause of bone marrow suppression in this patient.

LIVER AND SYSTEMIC DISEASES

05-09

Sebati Özdemir

REVIEW Nobel Med 2013; 9(2): 5-9

AGING KIDNEY: SENESCENCE OR DISEASE?

10-14

Meltem Gürsu, Rümeyza Kazancıoğlu, Savaş Öztürk

REVIEW Nobel Med 2013; 9(2): 10-14

IMPORTANCE OF HOLOTRANSCOBALAMIN (HOLOTC) MEASUREMENTS IN EARLY DIAGNOSIS OF COBALAMIN DEFICIENCY, ESPECIALLY IN PATIENTS WITH BORDERLINE VITAMIN B12 CONCENTRATIONS

15-20

Faruk Sönmezışık, Esma Sürmen Gür, Burak Asıltaş

RESEARCH ARTICLE Nobel Med 2013; 9(2): 15-20

EVALUATION OF PHYSICAL GROWTH IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

21-25

Celalettin Koşan, Oğuzhan Sepetçigil, Atilla Çayır, Avni Kaya, Behzat Özkan

RESEARCH ARTICLE Nobel Med 2013; 9(2): 21-25

COMPARISON OF RISK INDEXES USED IN DETERMINING THE POSTOPERATIVE RESPIRATORY INSUFFICIENCY RISK

26-31

Gülsüm Kavalcı, Cavidan Arar, Alkın Çolak, Nesrin Turan, Cemil Kavalcı

RESEARCH ARTICLE Nobel Med 2013; 9(2): 26-31

THE EVALUATION OF PRENATAL AND ENVIROMENTAL RISK FACTORS IN CHILDREN WITH ASTHMA, ALLERGIC RHINITIS AND BRONCHIAL ASTHMA ABSTRACT

32-37

Mehmet İbrahim Turan, Müferet Ergüven, Mehmet Özdemir

RESEARCH ARTICLE Nobel Med 2013; 9(2): 32-37

REOPERATIONS AND MORBIDITY IN THYROID SURGERY

38-42

Serkan Teksöz, Murat Özcan, Aytül Sargan, Yusuf Bukey, Recep Özgültekin, Ateş Özyeğin

RESEARCH ARTICLE Nobel Med 2013; 9(2): 38-42

EFFECTS OF RAMADAN FASTING ON BLOOD PRESSURE CONTROL, LIPID PROFILE, BRAIN NATRIURETIC PEPTIDE, RENAL FUNCTIONS AND ELECTROLYTE LEVELS IN HYPERTENSIVE PATIENTS TAKING COMBINATION THERAPY

43-46

İbrahim Faruk Aktürk, İsmail Bıyık, Cüneyt Koşaş, Ahmet Arif Yalçın, Mehmet Ertürk, Fatih Uzun

RESEARCH ARTICLE Nobel Med 2013; 9(2): 43-46

MANAGEMENT OF A LARGE OUTBREAK CAUSED BY NOROVIRUS AND CAMPYLOBACTER JEJUNI OCCURRED IN A RURAL AREA IN TURKEY

47-51

İbak Gönen

RESEARCH ARTICLE Nobel Med 2013; 9(2): 47-51

FREQUENT CD99 AND FLI-1 EXPRESSIONS IN DIFFUSE LARGE B-CELL LYMPHOMA AND THEIR ASSOCIATION WITH PROLIFERATIVE AND APOPTOTIC RATES

52-56

Ufuk Berber, İsmail Yılmaz, Tolga Tuncel, Zafer Küçükodacı Aptullah Haholu

RESEARCH ARTICLE Nobel Med 2013; 9(2): 52-56
  • Pubmed Style
    Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay. [PİPERASİLİN/TAZOBAKTAMA BAĞLI KEMİK İLİĞİ BASKILANMASI İLE SEYREDEN BİR OLGU SUNUMU ]. Nobel Med 2008; 4(1): 28-30, Turkish.
  • Web Style
    Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay. [PİPERASİLİN/TAZOBAKTAMA BAĞLI KEMİK İLİĞİ BASKILANMASI İLE SEYREDEN BİR OLGU SUNUMU ]. www.nobelmedicus.com/en/Article.aspx?m=1716 [Access: Mayıs 24, 2021], Turkish.
  • AMA (American Medical Association) Style
    Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay. [PİPERASİLİN/TAZOBAKTAMA BAĞLI KEMİK İLİĞİ BASKILANMASI İLE SEYREDEN BİR OLGU SUNUMU ]. Nobel Med 2008; 4(1): 28-30, Turkish.
  • Vancouver/ICMJE Style
    Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay. [PİPERASİLİN/TAZOBAKTAMA BAĞLI KEMİK İLİĞİ BASKILANMASI İLE SEYREDEN BİR OLGU SUNUMU ]. Nobel Med (2008); 4(1): 28-30, [cited Mayıs 24, 2021], Turkish.
  • Harvard Style
    Ahmet Ekmekçi, Fatih Yakar, Fatih Tufan, Mustafa Demirtürk, Atahan Çağatay. (2008) [PİPERASİLİN/TAZOBAKTAMA BAĞLI KEMİK İLİĞİ BASKILANMASI İLE SEYREDEN BİR OLGU SUNUMU ]. Nobel Med, 4(1): 28-30, Turkish.